Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Forte Biosciences, Inc. Director's Dealing 2018

Jun 25, 2018

33769_dirs_2018-06-25_39004a5b-1acf-4a19-810f-b036d498bc37.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2018-06-21

Reporting Person: BERGER FRANKLIN M (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-06-21 Stock option (right to buy) $8.98 A 20000 Acquired 2028-06-20 Common Stock (20000) Direct

Footnotes

F1: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant.